Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia
Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia
Status: Enrolling
Updated:  2/8/2011
University of Pittsburgh
mi
from
Pittsburgh, PA
Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia
Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia
Status: Enrolling
Updated: 2/8/2011
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
Status: Enrolling
Updated:  2/16/2011
University of Pittsburgh
mi
from
Pittsburgh, PA
Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
Status: Enrolling
Updated: 2/16/2011
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Web-Based Weight Management for Individuals With Mental Illness
Web-Based Weight Management for Individuals With Mental Illness
Status: Enrolling
Updated:  3/28/2011
UCLA Center for Health Services and Society
mi
from
Los Angeles, CA
Web-Based Weight Management for Individuals With Mental Illness
Web-Based Weight Management for Individuals With Mental Illness
Status: Enrolling
Updated: 3/28/2011
UCLA Center for Health Services and Society
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Benefits Management for People With Psychiatric Disabilities
Benefits Management for People With Psychiatric Disabilities
Status: Enrolling
Updated:  4/1/2011
Institute of Living
mi
from
Hartford, CT
Benefits Management for People With Psychiatric Disabilities
Benefits Management for People With Psychiatric Disabilities
Status: Enrolling
Updated: 4/1/2011
Institute of Living
mi
from
Hartford, CT
Click here to add this to my saved trials
Effects of Paliperidone Palmitate Versus Oral Antipsychotics on Clinical Outcomes and MRI Measures
Effects of Paliperidone Palmitate Versus Oral Antipsychotics on Clinical Outcome and sMR Measures in First Episode Patients: A Randomized Clinical Trial
Status: Enrolling
Updated:  5/23/2011
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Effects of Paliperidone Palmitate Versus Oral Antipsychotics on Clinical Outcomes and MRI Measures
Effects of Paliperidone Palmitate Versus Oral Antipsychotics on Clinical Outcome and sMR Measures in First Episode Patients: A Randomized Clinical Trial
Status: Enrolling
Updated: 5/23/2011
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Cognitive Skills Training Using Computer for Patients With Severe Mental Illness
Computerized Cognitive Skills Training in Severe Mental Illness
Status: Enrolling
Updated:  6/2/2011
Manhattan Psychiatric Center
mi
from
New York, NY
Cognitive Skills Training Using Computer for Patients With Severe Mental Illness
Computerized Cognitive Skills Training in Severe Mental Illness
Status: Enrolling
Updated: 6/2/2011
Manhattan Psychiatric Center
mi
from
New York, NY
Click here to add this to my saved trials
D-serine for the Schizophrenia Prodrome
D-Serine vs Placebo for the Schizophrenia Prodrome
Status: Enrolling
Updated:  6/6/2011
Yale University
mi
from
New Haven, CT
D-serine for the Schizophrenia Prodrome
D-Serine vs Placebo for the Schizophrenia Prodrome
Status: Enrolling
Updated: 6/6/2011
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
D-serine for the Schizophrenia Prodrome
D-Serine vs Placebo for the Schizophrenia Prodrome
Status: Enrolling
Updated:  6/6/2011
The Zucker Hillside Hospital
mi
from
Glen Oaks, NY
D-serine for the Schizophrenia Prodrome
D-Serine vs Placebo for the Schizophrenia Prodrome
Status: Enrolling
Updated: 6/6/2011
The Zucker Hillside Hospital
mi
from
Glen Oaks, NY
Click here to add this to my saved trials
D-serine for the Schizophrenia Prodrome
D-Serine vs Placebo for the Schizophrenia Prodrome
Status: Enrolling
Updated:  6/6/2011
New York State Psychiatric Institute
mi
from
New York, NY
D-serine for the Schizophrenia Prodrome
D-Serine vs Placebo for the Schizophrenia Prodrome
Status: Enrolling
Updated: 6/6/2011
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
D-serine for the Schizophrenia Prodrome
D-Serine vs Placebo for the Schizophrenia Prodrome
Status: Enrolling
Updated:  6/6/2011
Nathan Kline Institute
mi
from
Orangeburg, NY
D-serine for the Schizophrenia Prodrome
D-Serine vs Placebo for the Schizophrenia Prodrome
Status: Enrolling
Updated: 6/6/2011
Nathan Kline Institute
mi
from
Orangeburg, NY
Click here to add this to my saved trials
The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels
The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels
Status: Enrolling
Updated:  6/28/2011
Weill-Cornell Medical College
mi
from
New York, NY
The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels
The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels
Status: Enrolling
Updated: 6/28/2011
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder
The Effects of Ziprasidone 320 mg on Glucose and Plasma Lipids in Patients With Diabetes Type II and Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  7/28/2011
Manhattan Psychiatric Center
mi
from
New York, NY
Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder
The Effects of Ziprasidone 320 mg on Glucose and Plasma Lipids in Patients With Diabetes Type II and Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 7/28/2011
Manhattan Psychiatric Center
mi
from
New York, NY
Click here to add this to my saved trials
Oxytocin Add on Study for Stable Schizophrenic Patients
Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study of Intranasal Oxytocin Augmentation of Antipsychotic Medication in Schizophrenia Patients
Status: Enrolling
Updated:  8/8/2011
University of California at San Diego
mi
from
San Diego, CA
Oxytocin Add on Study for Stable Schizophrenic Patients
Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study of Intranasal Oxytocin Augmentation of Antipsychotic Medication in Schizophrenia Patients
Status: Enrolling
Updated: 8/8/2011
University of California at San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Pharmacological Approach to Improve the Outcome of Social Cognition Training
Pharmacological Approach to Improve the Outcome of Social Cognition Training
Status: Enrolling
Updated:  1/19/2012
West Los Angeles VA Medical Center
mi
from
Los Angeles, CA
Pharmacological Approach to Improve the Outcome of Social Cognition Training
Pharmacological Approach to Improve the Outcome of Social Cognition Training
Status: Enrolling
Updated: 1/19/2012
West Los Angeles VA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Once-Daily Asenapine for Schizophrenia
A Randomized Comparison of Twice-Daily Versus Once-Daily Asenapine for Schizophrenia
Status: Enrolling
Updated:  3/6/2012
Central Regional Hospital
mi
from
Butner, NC
Once-Daily Asenapine for Schizophrenia
A Randomized Comparison of Twice-Daily Versus Once-Daily Asenapine for Schizophrenia
Status: Enrolling
Updated: 3/6/2012
Central Regional Hospital
mi
from
Butner, NC
Click here to add this to my saved trials
Zyprexa and Task Engagement in Schizophrenia
Efficacy of Olanzapine in Improving Task Engagement in Schizophrenia
Status: Enrolling
Updated:  3/16/2012
Columbia University Medical Center
mi
from
New York, NY
Zyprexa and Task Engagement in Schizophrenia
Efficacy of Olanzapine in Improving Task Engagement in Schizophrenia
Status: Enrolling
Updated: 3/16/2012
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Minocycline Augmentation in Schizophrenia
Minocycline Augmentation in Early-Course Schizophrenia
Status: Enrolling
Updated:  3/22/2012
Harris County Psychiatric Center
mi
from
Houston, TX
Minocycline Augmentation in Schizophrenia
Minocycline Augmentation in Early-Course Schizophrenia
Status: Enrolling
Updated: 3/22/2012
Harris County Psychiatric Center
mi
from
Houston, TX
Click here to add this to my saved trials
Factors Association With Poor Physical Function in Older Adults With Schizophrenia
The Impact of Neurocognition and Symptomatology on Physical Function Among Older Adults With Schizophrenia
Status: Enrolling
Updated:  4/2/2012
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Factors Association With Poor Physical Function in Older Adults With Schizophrenia
The Impact of Neurocognition and Symptomatology on Physical Function Among Older Adults With Schizophrenia
Status: Enrolling
Updated: 4/2/2012
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety, Tolerability and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Two Iloperidone Depot Formulations Followed by a Dose-ranging Phase of One Selected Formulation in Schizophrenic Patients Given Depot Injections Every 28 Days
Status: Enrolling
Updated:  4/24/2012
Parexel, 1560 East Chevy Chase Drive, #140,
mi
from
Glendale, CA
Safety, Tolerability and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Two Iloperidone Depot Formulations Followed by a Dose-ranging Phase of One Selected Formulation in Schizophrenic Patients Given Depot Injections Every 28 Days
Status: Enrolling
Updated: 4/24/2012
Parexel, 1560 East Chevy Chase Drive, #140,
mi
from
Glendale, CA
Click here to add this to my saved trials
Safety, Tolerability and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Two Iloperidone Depot Formulations Followed by a Dose-ranging Phase of One Selected Formulation in Schizophrenic Patients Given Depot Injections Every 28 Days
Status: Enrolling
Updated:  4/24/2012
University of California - Irvine, Main Centre, 5251 California Avenue, Ste 240
mi
from
Irvine, CA
Safety, Tolerability and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Two Iloperidone Depot Formulations Followed by a Dose-ranging Phase of One Selected Formulation in Schizophrenic Patients Given Depot Injections Every 28 Days
Status: Enrolling
Updated: 4/24/2012
University of California - Irvine, Main Centre, 5251 California Avenue, Ste 240
mi
from
Irvine, CA
Click here to add this to my saved trials
Safety, Tolerability and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Two Iloperidone Depot Formulations Followed by a Dose-ranging Phase of One Selected Formulation in Schizophrenic Patients Given Depot Injections Every 28 Days
Status: Enrolling
Updated:  4/24/2012
CRI WorldWide, 1113 Hospital Drive
mi
from
Willingboro, NJ
Safety, Tolerability and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Two Iloperidone Depot Formulations Followed by a Dose-ranging Phase of One Selected Formulation in Schizophrenic Patients Given Depot Injections Every 28 Days
Status: Enrolling
Updated: 4/24/2012
CRI WorldWide, 1113 Hospital Drive
mi
from
Willingboro, NJ
Click here to add this to my saved trials
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia
Status: Enrolling
Updated:  4/26/2012
Freedom Trail Clinic
mi
from
Boston, MA
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia
Status: Enrolling
Updated: 4/26/2012
Freedom Trail Clinic
mi
from
Boston, MA
Click here to add this to my saved trials
Brain Myelination Effects of Paliperidone Palmitate Versus Oral Risperidone in First Episode Schizophrenia
Brain Myelination Effects of Paliperidone Palmitate vs. Oral Risperidone in First Episode Schizophrenia
Status: Enrolling
Updated:  6/14/2012
UCLA Semel Institute for Neuroscience and Human Behavior
mi
from
Los Angeles, CA
Brain Myelination Effects of Paliperidone Palmitate Versus Oral Risperidone in First Episode Schizophrenia
Brain Myelination Effects of Paliperidone Palmitate vs. Oral Risperidone in First Episode Schizophrenia
Status: Enrolling
Updated: 6/14/2012
UCLA Semel Institute for Neuroscience and Human Behavior
mi
from
Los Angeles, CA
Click here to add this to my saved trials
First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia
Phase I, Randomized, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 579 in Healthy Adult Subjects and Patients With Stable Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  7/13/2012
Clinical Research Facility
mi
from
San Diego, CA
First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia
Phase I, Randomized, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 579 in Healthy Adult Subjects and Patients With Stable Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 7/13/2012
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/13/2012
Clinical Research Facility
mi
from
Los Angeles, CA
A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/13/2012
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/13/2012
Clinical Research Facility
mi
from
Miami, FL
A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/13/2012
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/13/2012
Clinical Research Facility
mi
from
Topeka, KA
A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/13/2012
Clinical Research Facility
mi
from
Topeka, KA
Click here to add this to my saved trials
A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/13/2012
Clinical Research Facility
mi
from
Bethesda, MD
A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/13/2012
Clinical Research Facility
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/13/2012
Clinical Research Facility
mi
from
Kansas City, MO
A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/13/2012
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/13/2012
Clinical Research Facility
mi
from
Philadelphia, PA
A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/13/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/13/2012
Clinical Research Facility
mi
from
Fort Worth, TX
A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/13/2012
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia
A Pilot, Open-Label, Non-Randomized, Single Ascending Dose, Safety and Pharmacokinetic Trial With Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Chronic, Stable Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  7/16/2012
Glendale Adventist Medical Center
mi
from
Glendale, CA
A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia
A Pilot, Open-Label, Non-Randomized, Single Ascending Dose, Safety and Pharmacokinetic Trial With Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Chronic, Stable Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 7/16/2012
Glendale Adventist Medical Center
mi
from
Glendale, CA
Click here to add this to my saved trials
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia
Status: Enrolling
Updated:  7/17/2012
Yale University
mi
from
New Haven, CT
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia
Status: Enrolling
Updated: 7/17/2012
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
Biological and Behavioral Mechanisms of Smoking in Schizophrenia
Status: Enrolling
Updated:  7/26/2012
Brown University, 121 South Main Street
mi
from
Providence, RI
Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
Biological and Behavioral Mechanisms of Smoking in Schizophrenia
Status: Enrolling
Updated: 7/26/2012
Brown University, 121 South Main Street
mi
from
Providence, RI
Click here to add this to my saved trials
Specialized Treatment Early in Psychosis (STEP)
Randomized Trial of Usual Care Versus Specialized, Phase-specific Care in the Public Sector for First Episode Psychosis.
Status: Enrolling
Updated:  8/9/2012
Connecticut Mental Health Center
mi
from
New Haven, CT
Specialized Treatment Early in Psychosis (STEP)
Randomized Trial of Usual Care Versus Specialized, Phase-specific Care in the Public Sector for First Episode Psychosis.
Status: Enrolling
Updated: 8/9/2012
Connecticut Mental Health Center
mi
from
New Haven, CT
Click here to add this to my saved trials
A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence
A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence
Status: Enrolling
Updated:  9/6/2012
Veteran's Affairs Medical Center
mi
from
Denver, CO
A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence
A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence
Status: Enrolling
Updated: 9/6/2012
Veteran's Affairs Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Fayetteville, AR
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Fayetteville, AR
Click here to add this to my saved trials
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Washington,
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Miami, FL
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Athens, GA
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Athens, GA
Click here to add this to my saved trials
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Topeka, KA
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Topeka, KA
Click here to add this to my saved trials
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Alexandria, LA
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Alexandria, LA
Click here to add this to my saved trials
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Kansas City, MO
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Bridgewater, NJ
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Bridgewater, NJ
Click here to add this to my saved trials
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Brooklyn, NY
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Fort Worth, TX
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Norfolk, VA
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials